Market Cap : 159.91 B | Enterprise Value : 191.14 B | PE Ratio : 24.89 | PB Ratio : 4.91 |
---|
NYSE:BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bristol-Myers Squibb Co has the Growth Rank of 9.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Growth Rank distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Growth Rank falls into.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenlees Sharon | officer: SVP & Controller | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Shanahan Karin | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Meyers Gregory Scott | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Weese Michelle | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Hidalgo Medina Manuel | director | BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016 |
Rice Derica W | director | 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403 |
Price Paula A | director | ONE CVS DRIVE WOONSOCKET RI 02895 |
Mily Elizabeth | officer: EVP, Strategy & BD | BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540 |
Metcalfe Kathryn | officer: EVP, Corporate Affairs | BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543 |
Vessey Rupert | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Elkins David V | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417 |
Bonney Michael W | director | 65 HAYDEN AVE LEXINGTON MA 02421 |
Yale Phyllis R | director | |
Ahmed Nadim | officer: President, Hematology | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
Haller Julia A | director | C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901 |
From GuruFocus
Other Sources
By Zacks 2022-03-15
By Zacks 2022-03-16
By Zacks 2022-03-16
By Zacks 2022-04-04
By Zacks 2022-03-21
By Zacks 2022-03-16
By Zacks 2022-03-30
By Zacks 2022-03-29
By Zacks 2022-03-22
By Fool 2022-03-31
By Zacks 2022-03-23
By Fool 2022-03-29